Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Oct 2012
Multicenter Study Comparative StudyPrediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death.
The aim of this study was to derive and validate a practical risk model to predict death within 4 years of primary prevention implantable cardioverter-defibrillator (ICD) implantation. ⋯ This useful model, based on more than 45,000 primary prevention ICD patients, accurately identifies patients at highest risk for death after device implantation and may significantly influence clinical decision making.
-
J. Am. Coll. Cardiol. · Oct 2012
Multicenter Study Comparative StudyPre-procedural risk quantification for carotid stenting using the CAS score: a report from the NCDR CARE Registry.
We developed and internally validated a risk score to predict in-hospital stroke or death after carotid artery stenting (CAS). ⋯ The NCDR CAS score, comprising 6 clinical variables, predicts in-hospital S/D after CAS. This tool may be useful to assist clinicians in evaluating optimal management, share more accurate pre-procedural risks with patients, and improve patient selection for CAS.
-
J. Am. Coll. Cardiol. · Oct 2012
Randomized Controlled Trial Multicenter Study Comparative StudyA new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. ⋯ E-ZES+3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET]; NCT01145079).
-
J. Am. Coll. Cardiol. · Oct 2012
Randomized Controlled Trial Multicenter Study Comparative StudyImpact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial.
The goal of this study was to make a head-to-head comparison of 2 common forms of multidisciplinary chronic heart failure (CHF) management. ⋯ HBI was not superior to CBI in reducing all-cause death or hospitalization. However, HBI was associated with significantly lower healthcare costs, attributable to fewer days of hospitalization. (Which Heart failure Intervention is most Cost-effective & consumer friendly in reducing Hospital care [WHICH?]; ACTRN12607000069459).